desvenlafaxine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4380	93413-62-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: desvenlafaxine desvenlafaxine succinate pristiq DVS-233 desvenlafaxine fumarate	The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). Molecular weight: 263.38 Formula: C16H25NO2 CLOGP: 2.68 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 43.70 ALOGS: -2.27 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

desvenlafaxine
desvenlafaxine succinate
pristiq
DVS-233
desvenlafaxine fumarate

The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).

Molecular weight: 263.38
Formula: C16H25NO2
CLOGP: 2.68
LIPINSKI: 0
HAC: 3
HDO: 2
TPSA: 43.70
ALOGS: -2.27
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
50	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	572 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	45 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	5.42 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	3.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	4.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.70 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	8.40 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 29, 2008	FDA	WYETH PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product residue present	757.98	15.43	197	23013	3598	56265259
Drug withdrawal syndrome	644.04	15.43	279	22931	25578	56243279
Suicidal ideation	360.42	15.43	249	22961	57493	56211364
Anxiety	327.42	15.43	400	22810	192772	56076085
Withdrawal syndrome	293.29	15.43	146	23064	18316	56250541
Feeling abnormal	285.56	15.43	312	22898	133290	56135567
Crying	283.97	15.43	150	23060	21290	56247567
Depression	251.51	15.43	339	22871	179778	56089079
Insomnia	216.08	15.43	326	22884	191534	56077323
Irritability	211.74	15.43	139	23071	29449	56239408
Dizziness	166.28	15.43	431	22779	375709	55893148
Anger	155.45	15.43	82	23128	11590	56257267
Nausea	132.38	15.43	642	22568	763536	55505321
Hyperhidrosis	114.46	15.43	166	23044	93922	56174935
Headache	110.74	15.43	489	22721	558555	55710302
Panic attack	101.85	15.43	77	23133	20370	56248487
Tremor	98.56	15.43	178	23032	120911	56147946
Nervousness	97.70	15.43	87	23123	28928	56239929
Agitation	94.46	15.43	116	23094	55920	56212937
Intentional product misuse	92.33	15.43	110	23100	51394	56217463
Emotional disorder	88.49	15.43	58	23152	12237	56256620
Condition aggravated	88.24	15.43	327	22883	344571	55924286
Abnormal dreams	85.69	15.43	52	23158	9597	56259260
Rheumatoid arthritis	78.31	15.43	30	23180	382574	55886283
Feeling jittery	72.80	15.43	51	23159	11995	56256862
Completed suicide	68.98	15.43	163	23047	133670	56135187
Nightmare	65.86	15.43	55	23155	16771	56252086
Thinking abnormal	64.57	15.43	44	23166	9897	56258960
Suicide attempt	63.06	15.43	97	23113	57739	56211118
Persistent genital arousal disorder	55.86	15.43	15	23195	311	56268546
Overdose	53.54	15.43	128	23082	105702	56163155
Disturbance in attention	52.63	15.43	66	23144	32474	56236383
Serotonin syndrome	51.49	15.43	59	23151	26431	56242426
Depressed mood	51.39	15.43	69	23141	36290	56232567
Synovitis	51.35	15.43	4	23206	161301	56107556
Paraesthesia	49.77	15.43	142	23068	130372	56138485
Middle insomnia	47.49	15.43	38	23172	10912	56257945
Impaired driving ability	46.79	15.43	26	23184	4070	56264787
Migraine	44.99	15.43	106	23104	86691	56182166
Seizure	44.69	15.43	133	23077	124986	56143871
Pyrexia	44.41	15.43	65	23145	418708	55850149
Systemic lupus erythematosus	44.29	15.43	10	23200	180068	56088789
Joint swelling	44.19	15.43	33	23177	289767	55979090
Vision blurred	43.76	15.43	102	23108	82841	56186016
Product substitution issue	43.71	15.43	41	23169	14558	56254299
Drug screen positive	42.36	15.43	23	23187	3441	56265416
Mania	41.69	15.43	36	23174	11484	56257373
Anaemia	41.38	15.43	30	23180	267481	56001376
Drug ineffective	41.22	15.43	567	22643	918422	55350435
Tinnitus	40.92	15.43	56	23154	29986	56238871
Mydriasis	40.88	15.43	35	23175	11036	56257821
Acute kidney injury	39.92	15.43	25	23185	240738	56028119
Anorgasmia	39.52	15.43	13	23197	552	56268305
Energy increased	38.52	15.43	19	23191	2331	56266526
Coma scale abnormal	37.59	15.43	24	23186	4839	56264018
Somnolence	37.57	15.43	150	23060	163263	56105594
Infusion related reaction	37.03	15.43	20	23190	208911	56059946
Maternal exposure during pregnancy	36.86	15.43	16	23194	189537	56079320
Therapeutic response unexpected	36.61	15.43	40	23170	17004	56251853
Bruxism	35.90	15.43	20	23190	3146	56265711
Stomatitis	35.77	15.43	4	23206	120806	56148051
Mood altered	35.26	15.43	35	23175	13320	56255537
Pre-existing condition improved	34.94	15.43	27	23183	7371	56261486
Drug screen false positive	34.78	15.43	13	23197	807	56268050
Blood pressure increased	34.78	15.43	135	23075	145041	56123816
Aggression	34.57	15.43	44	23166	21962	56246895
Peripheral swelling	34.16	15.43	28	23182	234698	56034159
Pericarditis	33.83	15.43	3	23207	108920	56159937
General physical health deterioration	33.61	15.43	14	23196	169996	56098861
Death	33.31	15.43	56	23154	341370	55927487
Neutropenia	32.96	15.43	12	23198	158155	56110702
Restlessness	32.41	15.43	47	23163	26539	56242318
Treatment failure	32.16	15.43	15	23195	170377	56098480
Mood swings	32.04	15.43	37	23173	16710	56252147
Paranoia	31.83	15.43	30	23180	10714	56258143
Thrombocytopenia	30.74	15.43	9	23201	136215	56132642
Palpitations	30.10	15.43	100	23110	99572	56169285
Drug hypersensitivity	29.31	15.43	204	23006	275001	55993856
Mental disorder	29.17	15.43	42	23168	23562	56245295
Arthropathy	28.99	15.43	24	23186	200251	56068606
Lower respiratory tract infection	28.98	15.43	6	23204	114788	56154069
Amnesia	28.97	15.43	61	23149	46261	56222596
Yawning	28.27	15.43	12	23198	1041	56267816
Abnormal behaviour	27.92	15.43	38	23172	20234	56248623
Euphoric mood	27.61	15.43	19	23191	4339	56264518
Nonspecific reaction	27.28	15.43	14	23196	1867	56266990
Libido decreased	26.73	15.43	15	23195	2393	56266464
Weight increased	26.68	15.43	174	23036	229529	56039328
Infection	26.58	15.43	26	23184	200180	56068677
Stress	26.33	15.43	68	23142	58842	56210015
Tachyphrenia	25.98	15.43	12	23198	1272	56267585
Dissociation	25.73	15.43	15	23195	2570	56266287
Swelling	25.58	15.43	37	23173	239734	56029123
Hostility	24.76	15.43	13	23197	1818	56267039
Hypersensitivity vasculitis	24.13	15.43	17	23193	4031	56264826
Wound	23.56	15.43	14	23196	138790	56130067
Unevaluable event	23.36	15.43	57	23153	47630	56221227
Loss of libido	23.30	15.43	11	23199	1225	56267632
Panic reaction	22.64	15.43	16	23194	3814	56265043
Sepsis	22.50	15.43	15	23195	139825	56129032
Post-traumatic stress disorder	22.39	15.43	17	23193	4521	56264336
Bipolar disorder	22.14	15.43	21	23189	7559	56261298
Apathy	21.28	15.43	21	23189	7933	56260924
Hallucination	21.21	15.43	56	23154	49093	56219764
Glossodynia	21.17	15.43	19	23191	152439	56116418
Wrong technique in product usage process	20.90	15.43	62	23148	58106	56210751
Febrile neutropenia	20.36	15.43	9	23201	105536	56163321
Muscle twitching	20.21	15.43	29	23181	16213	56252644
Negative thoughts	20.21	15.43	9	23201	877	56267980
Hallucination, auditory	19.63	15.43	24	23186	11500	56257357
Memory impairment	19.50	15.43	79	23131	86478	56182379
Pneumonia	19.47	15.43	94	23116	407004	55861853
Brain injury	19.31	15.43	18	23192	6337	56262520
Tardive dyskinesia	19.29	15.43	20	23190	8011	56260846
Impaired healing	19.11	15.43	6	23204	86835	56182022
Malaise	18.85	15.43	233	22977	367627	55901230
Suicidal behaviour	18.79	15.43	12	23198	2421	56266436
Tearfulness	18.34	15.43	14	23196	3754	56265103
Arthralgia	18.04	15.43	127	23083	501542	55767315
Change in seizure presentation	17.91	15.43	6	23204	270	56268587
Intestinal pseudo-obstruction	17.87	15.43	8	23202	789	56268068
Abdominal discomfort	17.03	15.43	58	23152	277216	55991641
Drug dependence	16.88	15.43	32	23178	22501	56246356
Impaired work ability	16.66	15.43	25	23185	14547	56254310
Restless legs syndrome	16.49	15.43	27	23183	16920	56251937
Wrong strength	16.37	15.43	4	23206	56	56268801
Obsessive-compulsive disorder	16.36	15.43	13	23197	3693	56265164
Decreased interest	16.34	15.43	12	23198	3034	56265823
Dyspnoea	16.33	15.43	161	23049	592416	55676441
Blood triglycerides increased	16.25	15.43	22	23188	11655	56257202
Product prescribing error	16.23	15.43	32	23178	23154	56245703
Impatience	16.15	15.43	6	23204	366	56268491
Feeling drunk	16.10	15.43	13	23197	3779	56265078
Prescribed overdose	15.89	15.43	31	23179	22265	56246592
Galactorrhoea	15.80	15.43	13	23197	3882	56264975
Drug effective for unapproved indication	15.74	15.43	11	23199	2575	56266282
Wernicke-Korsakoff syndrome	15.70	15.43	4	23206	67	56268790
Heart rate increased	15.68	15.43	72	23138	83201	56185656
Pain	15.55	15.43	187	23023	662997	55605860
Affect lability	15.51	15.43	20	23190	10105	56258752

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product residue present	227.90	22.01	61	6476	2569	31688238
Serotonin syndrome	178.85	22.01	84	6453	18689	31672118
Drug withdrawal syndrome	166.68	22.01	80	6457	18670	31672137
Anxiety	120.30	22.01	119	6418	90914	31599893
Suicidal ideation	119.58	22.01	81	6456	36325	31654482
Depression	83.39	22.01	98	6439	90717	31600090
Hyperhidrosis	72.50	22.01	79	6458	67314	31623493
Overdose	67.34	22.01	85	6452	84579	31606228
Suicide attempt	61.12	22.01	55	6482	37193	31653614
Feeling abnormal	58.13	22.01	65	6472	56937	31633870
Sexual dysfunction	57.66	22.01	27	6510	5941	31684866
Insomnia	53.95	22.01	81	6456	94755	31596052
Withdrawal syndrome	50.58	22.01	31	6506	11686	31679121
Major depression	49.80	22.01	22	6515	4231	31686576
Anger	49.41	22.01	30	6507	11123	31679684
Panic attack	45.34	22.01	26	6511	8677	31682130
Drug ineffective	41.60	22.01	176	6361	395397	31295410
Thinking abnormal	41.19	22.01	21	6516	5552	31685255
Completed suicide	38.22	22.01	68	6469	91446	31599361
Nervousness	35.71	22.01	25	6512	11775	31679032
Schizophreniform disorder	35.64	22.01	7	6530	70	31690737
Erectile dysfunction	34.72	22.01	30	6507	19205	31671602
Coma scale abnormal	33.38	22.01	16	6521	3707	31687100
Mania	31.46	22.01	21	6516	9156	31681651
Dry mouth	30.39	22.01	31	6506	24427	31666380
Crying	29.90	22.01	17	6520	5580	31685227
Libido decreased	27.89	22.01	15	6522	4421	31686386
Headache	27.75	22.01	92	6445	183560	31507247
Tremor	27.15	22.01	53	6484	76367	31614440
Drug screen positive	26.98	22.01	14	6523	3838	31686969
Irritability	26.61	22.01	28	6509	22861	31667946
Drug interaction	25.95	22.01	98	6439	208445	31482362
Abnormal behaviour	25.68	22.01	28	6509	23800	31667007
Dizziness	25.12	22.01	94	6443	199053	31491754
Bipolar disorder	24.56	22.01	13	6524	3711	31687096
Paralysis	24.48	22.01	15	6522	5648	31685159
Drug screen false positive	24.23	22.01	8	6529	695	31690112
Intentional product misuse	23.82	22.01	34	6503	37917	31652890
Emotional disorder	22.93	22.01	14	6523	5235	31685572
Paraesthesia	22.52	22.01	41	6496	56030	31634777
Male sexual dysfunction	22.29	22.01	6	6531	257	31690550
Suicidal behaviour	22.05	22.01	9	6528	1423	31689384

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Withdrawal syndrome	279.02	15.16	136	19176	24768	70884364
Anxiety	247.62	15.16	302	19010	220028	70689104
Drug withdrawal syndrome	235.87	15.16	133	19179	32582	70876550
Suicidal ideation	231.38	15.16	174	19138	69422	70839710
Feeling abnormal	222.91	15.16	232	19080	142087	70767045
Depression	199.93	15.16	258	19054	198716	70710416
Crying	194.08	15.16	101	19211	21098	70888034
Product residue present	183.50	15.16	58	19254	3312	70905820
Serotonin syndrome	168.85	15.16	118	19194	41996	70867136
Irritability	132.36	15.16	98	19214	38127	70871005
Overdose	125.35	15.16	190	19122	169555	70739577
Anger	117.34	15.16	66	19246	16066	70893066
Insomnia	101.73	15.16	199	19113	217607	70691525
Suicide attempt	93.94	15.16	112	19200	79398	70829734
Completed suicide	91.24	15.16	195	19117	226940	70682192
Dizziness	84.78	15.16	298	19014	463843	70445289
Panic attack	84.03	15.16	60	19252	22059	70887073
Hyperhidrosis	81.50	15.16	136	19176	131450	70777682
Emotional disorder	77.39	15.16	47	19265	13179	70895953
Coma scale abnormal	69.51	15.16	37	19275	8079	70901053
Tremor	67.55	15.16	138	19174	155486	70753646
Headache	65.21	15.16	321	18991	580084	70329048
Intentional product misuse	64.27	15.16	93	19219	79502	70829630
Nervousness	64.04	15.16	59	19253	31061	70878071
Persistent genital arousal disorder	62.27	15.16	15	19297	306	70908826
Nausea	60.41	15.16	417	18895	851671	70057461
Drug ineffective	59.21	15.16	447	18865	939305	69969827
Drug hypersensitivity	58.99	15.16	181	19131	262278	70646854
Depressed mood	57.20	15.16	65	19247	43755	70865377
Thinking abnormal	55.95	15.16	37	19275	12014	70897118
Product substitution issue	54.26	15.16	43	19269	18470	70890662
Acute kidney injury	48.74	15.16	35	19277	474589	70434543
Abnormal dreams	47.89	15.16	32	19280	10571	70898561
Nightmare	47.52	15.16	43	19269	22113	70887019
Major depression	43.92	15.16	28	19284	8546	70900586
Impaired driving ability	41.19	15.16	22	19290	4835	70904297
Agitation	37.21	15.16	80	19232	93295	70815837
Migraine	36.08	15.16	68	19244	72170	70836962
Mental disorder	35.34	15.16	41	19271	28199	70880933
Anaemia	34.96	15.16	35	19277	403388	70505744
Feeling jittery	34.23	15.16	27	19285	11516	70897616
Thrombocytopenia	32.88	15.16	12	19300	239098	70670034
Mania	32.33	15.16	31	19281	17143	70891989
General physical health deterioration	32.20	15.16	12	19300	236019	70673113
Febrile neutropenia	32.18	15.16	8	19304	204310	70704822
Neutropenia	31.99	15.16	15	19297	257141	70651991
Tinnitus	31.74	15.16	44	19268	36132	70873000
Mood altered	31.51	15.16	30	19282	16445	70892687
Mood swings	30.69	15.16	31	19281	18255	70890877
Paranoia	30.29	15.16	30	19282	17258	70891874
Disturbance in attention	30.15	15.16	47	19265	42847	70866285
Pre-existing condition improved	29.84	15.16	18	19294	4984	70904148
Panic reaction	29.77	15.16	17	19295	4254	70904878
Condition aggravated	29.34	15.16	208	19104	427427	70481705
Pyrexia	28.89	15.16	78	19234	606874	70302258
Abnormal behaviour	28.64	15.16	41	19271	34668	70874464
Schizophreniform disorder	28.64	15.16	7	19305	152	70908980
Seizure	27.92	15.16	109	19203	177853	70731279
Hostility	27.30	15.16	13	19299	2242	70906890
Therapeutic response unexpected	27.17	15.16	29	19283	18202	70890930
Prescribed overdose	26.80	15.16	35	19277	27146	70881986
Rheumatoid arthritis	26.80	15.16	24	19288	291781	70617351
Memory impairment	25.71	15.16	69	19243	92572	70816560
Sepsis	25.10	15.16	18	19294	244527	70664605
Tardive dyskinesia	24.76	15.16	21	19291	9908	70899224
Contraindicated product administered	23.82	15.16	4	19308	134608	70774524
Suicidal behaviour	23.57	15.16	13	19299	3043	70906089
Drug effective for unapproved indication	23.40	15.16	15	19297	4620	70904512
Bipolar disorder	23.00	15.16	18	19294	7590	70901542
Paraesthesia	22.70	15.16	89	19223	145448	70763684
Synovitis	22.51	15.16	4	19308	129224	70779908
Hypersensitivity vasculitis	22.50	15.16	17	19295	6805	70902327
Dissociation	22.36	15.16	13	19299	3363	70905769
Affect lability	22.36	15.16	20	19292	10126	70899006
Reversible cerebral vasoconstriction syndrome	22.31	15.16	12	19300	2673	70906459
Drug dependence	22.30	15.16	38	19274	37283	70871849
Renal impairment	21.96	15.16	6	19306	143931	70765201
Stress	21.30	15.16	53	19259	67913	70841219
Product dose omission issue	21.30	15.16	116	19196	217352	70691780
Bruxism	21.17	15.16	13	19299	3716	70905416
Amnesia	21.13	15.16	45	19267	52110	70857022
Aggression	21.03	15.16	43	19269	48403	70860729
Hypersomnia	20.88	15.16	27	19285	20737	70888395
Palpitations	20.86	15.16	72	19240	110681	70798451
Malignant neoplasm progression	20.71	15.16	4	19308	121735	70787397
Malaise	20.68	15.16	194	19118	432738	70476394
Renal failure	20.63	15.16	13	19299	189057	70720075
Frustration tolerance decreased	20.44	15.16	16	19296	6749	70902383
Yawning	20.43	15.16	9	19303	1298	70907834
Drug screen positive	20.26	15.16	15	19297	5825	70903307
Self-injurious ideation	19.88	15.16	12	19300	3326	70905806
Multiple organ dysfunction syndrome	19.70	15.16	3	19309	108512	70800620
Product dispensing error	19.50	15.16	20	19292	11988	70897144
Change in seizure presentation	19.39	15.16	6	19306	319	70908813
Bradycardia	19.38	15.16	5	19307	124610	70784522
Impaired work ability	19.24	15.16	23	19289	16317	70892815
Energy increased	18.82	15.16	11	19301	2873	70906259
Mental impairment	18.24	15.16	23	19289	17232	70891900
Wrong strength	18.12	15.16	5	19307	177	70908955
Systemic lupus erythematosus	18.09	15.16	3	19309	101899	70807233
Road traffic accident	17.75	15.16	33	19279	34649	70874483
Muscle twitching	17.21	15.16	24	19288	19803	70889329
Wernicke-Korsakoff syndrome	17.18	15.16	4	19308	70	70909062
Ankyloglossia congenital	16.80	15.16	3	19309	12	70909120
Dyspnoea	16.75	15.16	132	19180	769928	70139204
False positive investigation result	16.73	15.16	7	19305	891	70908241
Joint swelling	16.68	15.16	27	19285	253184	70655948
Impulsive behaviour	16.66	15.16	10	19302	2744	70906388
Somnolence	16.61	15.16	108	19204	215498	70693634
Death	16.56	15.16	77	19235	509984	70399148
Septic shock	16.53	15.16	5	19307	112253	70796879
Vision blurred	16.39	15.16	60	19252	94924	70814208
Hypotension	16.32	15.16	56	19256	404325	70504807
Emotional distress	16.13	15.16	33	19279	37155	70871977
Infusion related reaction	16.11	15.16	18	19294	197516	70711616
Brain injury	16.02	15.16	17	19295	10600	70898532
Paralysis	15.90	15.16	18	19294	12054	70897078
Therapeutic response changed	15.55	15.16	7	19305	1062	70908070
Intestinal pseudo-obstruction	15.51	15.16	9	19303	2321	70906811
Anorgasmia	15.45	15.16	7	19305	1078	70908054
Hyperkalaemia	15.24	15.16	5	19307	106586	70802546
Dry mouth	15.23	15.16	48	19264	70409	70838723
Toxicity to various agents	15.22	15.16	165	19147	382007	70527125

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06AX23	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Other antidepressants
FDA MoA	N0000000102	Norepinephrine Uptake Inhibitors
FDA MoA	N0000000109	Serotonin Uptake Inhibitors
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D000068760	Serotonin and Noradrenaline Reuptake Inhibitors
FDA EPC	N0000175749	Serotonin and Norepinephrine Reuptake Inhibitor
FDA MoA	N0000182137	Cytochrome P450 2D6 Inhibitors
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:49103	drug metabolites
CHEBI has role	CHEBI:83399	marine xenobiotic metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Major depressive disorder	indication	370143000
Generalized anxiety disorder	off-label use	21897009	DOID:14320
Social phobia	off-label use	25501002	DOID:11257
Menopausal flushing	off-label use	198436008
Neuropathic pain	off-label use	247398009
Panic disorder	off-label use	371631005	DOID:594
Ocular hypertension	contraindication	4210003	DOID:9282
Suicidal thoughts	contraindication	6471006
Hypercholesterolemia	contraindication	13644009
Bipolar disorder	contraindication	13746004	DOID:3312
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Hypertensive disorder	contraindication	38341003	DOID:10763
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Syndrome of inappropriate vasopressin secretion	contraindication	55004003	DOID:3401
Cerebrovascular disease	contraindication	62914000	DOID:6713
Blood coagulation disorder	contraindication	64779008	DOID:1247
Hyponatremia	contraindication	89627008
Seizure disorder	contraindication	128613002
Bleeding	contraindication	131148009
Impaired renal function disorder	contraindication	197663003
Mania	contraindication	231494001
Hypomania	contraindication	231496004
Interstitial lung disease	contraindication	233703007	DOID:3082
Disease of liver	contraindication	235856003	DOID:409
Hypertriglyceridemia	contraindication	302870006
Serotonin syndrome	contraindication	371089000
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Myocardial infarction in recovery phase	contraindication	418044006
Hypertensive urgency	contraindication	443482000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.79	acidic
pKa2	9.33	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 100MG BASE	PRISTIQ	PF PRISM CV	N021992	Feb. 29, 2008	RX	TABLET, EXTENDED RELEASE	ORAL	6673838	March 1, 2022	FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
EQ 100MG BASE	PRISTIQ	PF PRISM CV	N021992	Feb. 29, 2008	RX	TABLET, EXTENDED RELEASE	ORAL	6673838	March 1, 2022	MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 25MG BASE	PRISTIQ	PF PRISM CV	N021992	Aug. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	6673838	March 1, 2022	FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
EQ 25MG BASE	PRISTIQ	PF PRISM CV	N021992	Aug. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	6673838	March 1, 2022	MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 50MG BASE	PRISTIQ	PF PRISM CV	N021992	Feb. 29, 2008	RX	TABLET, EXTENDED RELEASE	ORAL	6673838	March 1, 2022	FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
EQ 50MG BASE	PRISTIQ	PF PRISM CV	N021992	Feb. 29, 2008	RX	TABLET, EXTENDED RELEASE	ORAL	6673838	March 1, 2022	MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	Ki	7.33	WOMBAT-PK	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Ki	6.28	WOMBAT-PK	CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	7.22	CHEMBL

External reference:

ID	Source
D07793	KEGG_DRUG
4027338	VUID
N0000176142	NUI
386750-22-7	SECONDARY_CAS_RN
4027338	VANDF
C1880288	UMLSCUI
CHEBI:83527	CHEBI
CHEMBL1118	ChEMBL_ID
CHEMBL1201728	ChEMBL_ID
DB06700	DRUGBANK_ID
7158	IUPHAR_LIGAND_ID
8361	INN_ID
93414-04-1	SECONDARY_CAS_RN
NG99554ANW	UNII
125017	PUBCHEM_CID
683693	RXNORM
132507	MMSL
200628	MMSL
25184	MMSL
339716	MMSL
38906	MMSL
d07113	MMSL
012574	NDDF
012575	NDDF
015249	NDDF
430267008	SNOMEDCT_US
430271006	SNOMEDCT_US
433292007	SNOMEDCT_US
D000069468	MESH_DESCRIPTOR_UI
CHEMBL3989861	ChEMBL_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Pristiq Extended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0008-1210	TABLET, EXTENDED RELEASE	25 mg	ORAL	NDA	31 sections
Pristiq Extended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0008-1210	TABLET, EXTENDED RELEASE	25 mg	ORAL	NDA	31 sections
Pristiq Extended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0008-1211	TABLET, EXTENDED RELEASE	50 mg	ORAL	NDA	31 sections
Pristiq Extended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0008-1211	TABLET, EXTENDED RELEASE	50 mg	ORAL	NDA	31 sections
Pristiq Extended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0008-1222	TABLET, EXTENDED RELEASE	100 mg	ORAL	NDA	31 sections
Pristiq Extended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0008-1222	TABLET, EXTENDED RELEASE	100 mg	ORAL	NDA	31 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0400	TABLET, FILM COATED, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0401	TABLET, FILM COATED, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0603	TABLET, FILM COATED, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3659	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3659	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3660	TABLET, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3660	TABLET, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-4060	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-4060	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	35208-009	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	35208-010	TABLET, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
PristiqExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	43063-262	TABLET, EXTENDED RELEASE	50 mg	ORAL	NDA	31 sections
Desvenlafaxine	Human Prescription Drug Label	1	46708-152	TABLET, EXTENDED RELEASE	50 mg	ORAL	NDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	46708-153	TABLET, EXTENDED RELEASE	100 mg	ORAL	NDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	46708-540	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	46708-541	TABLET, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	46708-542	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4069	TABLET, EXTENDED RELEASE	50 mg	ORAL	NDA AUTHORIZED GENERIC	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4388	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4806	TABLET, FILM COATED, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	50090-5274	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	50090-5293	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	51407-021	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	51407-022	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections